Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
-$1.03 today
- Market cap
- $4.73B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
Volume 0.84M
Average 0.82M
DNTH Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Dianthus Therapeutics, Inc.NASDAQ: DNTH
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 735.2% from a year ago
Cash & equivalents stood at $110.55M at the end of Q2 FY2026, up 735.2% from a year earlier and down 82.4% from the prior quarter. Over 3 fiscal years it compounded at +49.3% a year.
Context
- Cash & equivalents amounted to 9.1% of total assets at the end of Q2 FY2026, up 5.1 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +735.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 51.09M USD
- Year-over-year change
- +124.1%
- 4-year CAGR
- -21.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 51.09M | +124.1% |
| FY2024 | 2024-12-31 | 22.79M | -82.8% |
| FY2023 | 2023-12-31 | 132.33M | +761.2% |
| FY2022 | 2022-12-31 | 15.37M | -88.3% |
| FY2021 | 2021-12-31 | 131.65M | — |
Cash & Equivalents vs competitors
How DNTH compares with its peers on the latest reported figures
- DNTH's Jun 2026 cash & equivalents of $110.55M is the 5th highest of the 10 companies compared; the peer median is $63.71M.
- Its year-over-year change of +735.2% is the highest of 10, against a peer median of -22.5%.
- Cash & equivalents amounts to 9.1% of total assets for DNTH, versus a peer median of 68.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $722.27M | +38.4% | +33.8% | 94.9% | |
| Mar 2026 | $298.49M | +9.9% | +103.8% | 74.6% | |
| Mar 2026 | $248.47M | +151.9% | +49.5% | 75.4% | |
| Mar 2026 | $118.64M | -34.2% | +5.5% | 41.1% | |
| Jun 2026 | $110.55M | +735.2% | +49.3% | 9.1% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $63.71M | -58.0% | +51.8% | 11.4% |
| Mar 2026 | $50.75M | -22.5% | +3.2% | 79.7% | |
| Jun 2026 | $48.88M | -0.5% | +101.3% | 9.2% | |
| Dec 2025 | $38.35M | -51.0% | -21.4% | 68.4% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $20.96M | -31.1% | -36.1% | 19.8% |
| Peer median (excluding DNTH) | $63.71M | -22.5% | +33.8% | 68.4% | |
Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 131.65M | 15.37M | 132.33M | 22.79M | 51.09M |
| Short-term Investments | 45.28M | 60.13M | 41.39M | 252.45M | 353.21M |
| Net Receivables | 0 | 5.64M | 478K | 807K | 102K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 3.77M | 53K | 504K | 355K | 5.04M |
| Total Current Assets | 180.69M | 82.03M | 177.45M | 280.9M | 409.44M |
| Property, Plant & Equipment (Net) | 7.46M | 956K | 800K | 1.75M | 1.63M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 1.78M | 0 | 0 | 81.73M | 110.14M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 121K | 1.15M | 9.63M | 9.72M |
| Total Non-current Assets | 9.24M | 1.08M | 1.95M | 93.1M | 121.48M |
| Total Assets | 189.93M | 83.11M | 179.41M | 374.01M | 530.92M |
| Account Payables | 3.04M | 1.17M | 2.61M | 4.58M | 9.73M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 100K | 100K | 479K | 1.19M |
| Other Current Liabilities | 4.48M | 2.08M | 5.36M | 5.15M | 9.52M |
| Total Current Liabilities | 10.86M | 8.23M | 9.63M | 18.45M | 30.73M |
| Long-term Debt | 0 | 0 | 0 | 0 | 1.02M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 791K | 736K | 1.91M | 5.77M |
| Other Non-current Liabilities | 6.4M | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 6.4M | 1.23M | 904K | 3.08M | 6.79M |
| Total Liabilities | 17.26M | 9.45M | 10.54M | 21.53M | 37.52M |
| Common Stock | 59K | 0 | 15K | 31K | 43K |
| Retained Earnings | (325.57M) | (45.87M) | (89.42M) | (174.39M) | (336.73M) |
| Accumulated OCI | (30K) | (161K) | 47K | 106K | 489K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 172.67M | 73.66M | 168.87M | 352.48M | 493.4M |
| Total Debt | 0 | 788K | 585K | 1.49M | 1.39M |
| Net Debt | (131.65M) | (14.58M) | (131.74M) | (21.3M) | (49.7M) |
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
Intrinsic Alpha fair value
Locked
Current Price
$83.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.